Bruker

Corporate brand

A global scientific-instrument manufacturer serving molecular, materials, life-science, industrial and applied-analysis markets.

Last updated August 31, 2026

AI crawler reads

2requests

1companies

Anthropic2

Profile: 2
Controversies: 0
JSON · MD: 0

First read: Nov 4, 2026
Latest read: Nov 4, 2026

From this site's server log

Overview

Bruker is a United States-headquartered scientific-instrument company whose origins are in nuclear magnetic resonance and electron-magnetic-resonance spectroscopy. Founded in Karlsruhe, Germany, in 1960 as Bruker-Physik AG, the company developed instrumentation for universities, government laboratories and industrial research organizations. It later broadened its portfolio into mass spectrometry, analytical X-ray systems, microscopy, spectroscopy, surface analysis, metrology, preclinical imaging and related software. The company is best known for high-end analytical platforms used to identify, characterize and measure molecules, materials and biological systems. Its principal technology areas include nuclear magnetic resonance spectroscopy, electron paramagnetic resonance, mass spectrometry, single-crystal and powder X-ray diffraction, X-ray fluorescence, X-ray microscopy and computed tomography, atomic-force microscopy, fluorescence and Raman microscopy, infrared spectroscopy, profilometry and industrial metrology. Bruker also supplies accessories, consumables, software, maintenance and application support around these systems. Bruker's early growth was driven by NMR innovation. The HFX 90, introduced in the 1960s, used semiconductor transistors and provided multiple independent channels. In 1969, Bruker introduced a commercial Fourier-transform NMR system, followed in the 1970s by superconducting Fourier-transform NMR instruments. These developments helped establish the company as a significant supplier to research institutions. Its United States presence began after early shipments to Yale University and the establishment of an office in Elmsford, New York. Over time, Bruker expanded through internal development and acquisitions. The company added analytical X-ray capabilities through the acquisition of Siemens's analytical X-ray business, strengthened its NMR activities through the GE NMR Instruments transaction, and acquired businesses and product lines in microscopy, imaging, metrology, superconducting technology, mass spectrometry and life-science analysis. A corporate reorganization completed in 2008 brought the operating activities under a more unified Bruker Corporation structure. Major operating groupings have included Bruker AXS, Bruker BioSpin, Bruker Daltonics, Bruker Optics and Bruker Energy & Supercon Technologies. The modern Bruker portfolio reaches beyond academic instrumentation. Its systems are used in pharmaceutical and biotechnology research, clinical and translational research, proteomics, metabolomics, materials science, geology, chemistry, semiconductor and industrial inspection, cultural-heritage analysis and environmental monitoring. Bruker instruments have also been selected for specialized research programs, including high-field Fourier-transform ion-cyclotron-resonance mass spectrometry and global greenhouse-gas observation networks. Bruker is a publicly traded company on the Nasdaq Global Select Market under the symbol BRKR. Its business model combines capital equipment with recurring service, software, consumables and application support. The company continues to position itself around high-performance analytical tools for difficult measurement problems, with growth supported by instrument replacement cycles, laboratory automation, biological research, advanced materials development and industrial quality control.

History

Bruker was established on September 7, 1960, in Karlsruhe, Germany, as Bruker-Physik AG. The founding group included Günther Laukien, then a professor at the University of Karlsruhe, and Emil Bruker, whose name became part of the corporate identity. The company initially focused on nuclear magnetic resonance and electron-magnetic-resonance spectroscopy equipment, serving the expanding market for advanced laboratory research. During the 1960s, Bruker grew rapidly and developed a reputation for engineering sophisticated NMR systems. Its HFX 90 system was an early notable product, using semiconductor transistors and offering three independent channels. In 1964, Bruker acquired the NMR division of Swiss company Trüb-Täuber. The company also began building a United States presence after shipping NMR systems to Yale University in 1968 and subsequently opening an office in Elmsford, New York. Bruker introduced a commercial Fourier-transform NMR system in 1969. During the following decade it became an early commercial supplier of superconducting Fourier-transform NMR instruments. These technologies helped researchers obtain more detailed information about molecular structure and dynamics. The company subsequently expanded into magnetic-resonance imaging, infrared and Raman spectroscopy, and mass spectrometry. Acquisitions became a major part of Bruker's development. It acquired GE NMR Instruments in 1992 and Siemens's analytical X-ray division in 1997, strengthening both its resonance and X-ray businesses. Other transactions added X-ray analysis, microscopy, superconducting technology, mass spectrometry, surface analysis and laboratory-instrument capabilities. The company acquired Nonius in 2001, MacScience in 2002, and a series of specialized businesses including Röntec, SOCABIM, PGT, Keymaster, Quantron, JuWe, SIS and ACCEL during the 2000s. In 2008, after a lengthy corporate reorganization, Bruker's divisions were consolidated under a more unified Bruker Corporation structure. In 2010, the company created a Chemical Analysis Division in Fremont, California, using product lines obtained from the former Varian business. These included inductively coupled plasma mass spectrometry and gas-chromatography-related products. Bruker continued to broaden its life-science and imaging presence through transactions involving Michrom Bioresources, SkyScan, Prairie Technologies and selected Carestream Health assets. The company pursued further expansion in the 2010s. It acquired or invested in businesses including Oncovision's preclinical PET imaging activities, Oxford Instruments Superconducting Technology, Hysitron, XGLab, Luxendo, Alicona and PMOD Technologies. Alicona strengthened Bruker's industrial metrology capabilities through focus-variation technology. Canopy Biosciences, acquired in 2020, added capabilities in single-cell and spatial biology. In 2022, Bruker acquired Optimal Group and Neurescence, and announced the acquisition of Inscopix, a developer of miniaturized neuroscience microscopy systems. More recent transactions extended Bruker's reach into cellular analysis, spatial biology and clinical diagnostics. The company acquired PhenomeX in 2023, made a majority investment in MIRO Analytical, acquired NanoString Technologies assets in 2024, and announced the acquisition of ELITechGroup in the same year. These moves reflect a strategy of combining core analytical-instrument businesses with adjacent technologies that support biological discovery and laboratory workflows. Bruker has also maintained links with the scientific community through prizes and sponsorships. It has sponsored the Günther Laukien Prize since 1999 and sponsored the Fritz Feigl Prize in 2012. Its instruments are used in university laboratories, national facilities, pharmaceutical research, industrial laboratories, environmental monitoring and specialized materials programs. Today, Bruker Corporation is headquartered in Billerica, Massachusetts, and operates internationally through businesses commonly associated with Bruker AXS, Bruker BioSpin, Bruker Daltonics, Bruker Optics and Bruker Energy & SuperCon Technologies.

2024
NanoString assets and ELITechGroup transactions announced
[2]Bruker investor relationsir.bruker.com
Bruker adds spatial-biology assets and broadens its clinical-diagnostics presence.
2023
PhenomeX acquired
[2]Bruker investor relationsir.bruker.com
Bruker expands into single-cell analysis and related life-science workflows.
2020
Canopy Biosciences acquired
[2]Bruker investor relationsir.bruker.com
The transaction adds single-cell and spatial biology capabilities.
2010
Chemical Analysis Division created
[1]Brukeren.wikipedia.org
Bruker establishes a Chemical Analysis Division in Fremont, California, incorporating selected former Varian product lines.
2008
Corporate reorganization completed
[1]Brukeren.wikipedia.org
An extended reorganization brings the main operating divisions under a more unified Bruker Corporation structure.
1997
Siemens analytical X-ray division acquired
[1]Brukeren.wikipedia.org
Bruker expands its analytical X-ray business through the acquisition of Siemens's division.
1992
GE NMR Instruments acquired
[1]Brukeren.wikipedia.org
The acquisition strengthens Bruker's position in NMR instrumentation.
1969
Commercial Fourier-transform NMR introduced
[1]Brukeren.wikipedia.org
Bruker launches an early commercial Fourier-transform NMR system.
1964
Acquisition of Trüb-Täuber's NMR division
[1]Brukeren.wikipedia.org
Bruker acquires the NMR division of the Swiss company Trüb-Täuber.
1960
Bruker-Physik AG is founded
[1]Brukeren.wikipedia.org
The company is established in Karlsruhe, Germany, with an initial focus on NMR and electron-magnetic-resonance spectroscopy equipment.

Products and positioning

High-performance scientific instrumentation for molecular, materials, life-science, industrial and applied research.

Molecular spectroscopy · 1960
NMR and EPR spectroscopy systems
Bruker's BioSpin business supplies nuclear magnetic resonance systems and related probes, magnets, consoles and software for chemistry, structural biology, metabolomics, pharmaceutical research and materials analysis. The broader resonance portfolio also includes electron paramagnetic resonance instruments for studying paramagnetic compounds, radicals and metal centers.
Mass spectrometry
Mass spectrometry platforms
Bruker Daltonics develops mass spectrometers and workflows for proteomics, microbiology, pharmaceutical research, metabolomics, imaging and chemical analysis. The portfolio includes high-resolution and specialized systems, ion sources, software and application solutions designed to measure molecular mass and structural information.
X-ray instrumentation · 1997
X-ray analysis systems
Bruker AXS provides single-crystal and powder X-ray diffractometers, X-ray fluorescence systems, X-ray microscopy and computed-tomography solutions. These instruments support crystallography, phase identification, elemental analysis, geological research, pharmaceutical development, materials science and industrial inspection.
Infrared and Raman spectroscopy
Optical spectroscopy systems
Bruker Optics supplies Fourier-transform infrared and Raman spectrometers for chemical identification, process monitoring, materials characterization, environmental analysis and research. The systems are offered with sampling accessories and software for laboratory, field and industrial applications.
Microscopy and metrology
Microscopy and surface-analysis systems
Bruker's microscopy portfolio includes atomic-force, fluorescence, Raman and related optical systems. Its surface-analysis and industrial businesses also provide profilometry, focus-variation metrology and nanoscale mechanical characterization for materials research, semiconductor work and manufacturing quality control.
Preclinical imaging
Preclinical and neuroscience imaging systems
Through acquisitions and specialized businesses, Bruker offers technologies for preclinical imaging and neuroscience research, including optical and miniaturized microscopy approaches. These systems are used to observe biological processes in animal models and to support translational research.

Marketing campaigns

2012Fritz Feigl Prize sponsorship
Global scientific community
Bruker sponsored the Fritz Feigl Prize, supporting recognition of achievement in analytical chemistry and related scientific fields.
Outcome. Scientific-community sponsorship
Source
1999Günther Laukien Prize sponsorship
Global scientific community
Bruker began sponsoring the Günther Laukien Prize, which recognizes contributions to NMR spectroscopy and helps connect the company with the international scientific community.
Outcome. Ongoing scientific-community engagement
Source

Brand decisions

2024
Expand into spatial biology and clinical diagnosticsM&A
Background
Bruker pursued adjacent growth areas in spatial biology and clinical laboratory testing.
Action taken
The company acquired NanoString Technologies assets and announced the acquisition of ELITechGroup.
Aftermath
The transactions broadened Bruker's life-science and diagnostics footprint beyond its traditional research-instrument categories.
Source
2023
Acquire PhenomeXM&A
Background
Single-cell analysis became an increasingly important area in life-science research and drug discovery.
Action taken
Bruker acquired PhenomeX to add single-cell biology tools and workflows.
Aftermath
The transaction strengthened Bruker's positioning in high-content biological analysis.
Source
2020
Acquire Canopy BiosciencesM&A
Background
Bruker sought to expand its life-science platform into single-cell and spatial biology.
Action taken
Bruker acquired Canopy Biosciences and integrated the business with its global infrastructure.
Aftermath
The acquisition broadened Bruker's product and application reach in advanced biological research; transaction terms were not disclosed.
Source
2010
Add selected former Varian analytical product linesM&A
Background
Agilent had acquired Varian and subsequently sold selected product lines, creating an opportunity for Bruker to broaden its chemical-analysis offering.
Action taken
Bruker created a Chemical Analysis Division and incorporated ICP-MS, laboratory gas chromatography and GC triple-quadrupole mass-spectrometry activities.
Aftermath
The move extended Bruker's portfolio beyond its traditional resonance, optical and molecular-analysis franchises.
Source
2008
Unify operating divisions under Bruker CorporationStrategy
Background
Bruker had undergone a prolonged corporate reorganization as its operating businesses expanded across spectroscopy, mass spectrometry, X-ray analysis and related technologies.
Action taken
The company consolidated its principal divisions into a more unified corporate structure.
Aftermath
The reorganization provided the structure used for subsequent expansion through acquisitions and broader global product integration.
Source

Recent events

2022.01.19
Bruker announces acquisition of Prolab Instruments[5]布鲁克宣布收购 Prolab Instrumentsselectscience.net
Bruker Corporation announced its acquisition of Prolab Instruments GmbH, a Swiss technology company specializing in low-flow liquid chromatography technology and systems. Financial terms were not disclosed.
2022.01.12
Reported2022.01.12
Bruker announces JPK NanoWizard V BioAFM release[6]Bruker宣布推出JPK NanoWizard V BioAFMnews-medical.net
Bruker announced the release of the JPK NanoWizard V BioAFM, an automated system for life science atomic force microscopy research.
2021.10.19
Reported2021.10.19
Bruker announces Dimension IconIR platform[7]布鲁克宣布推出 Dimension IconIR 平台azonano.com
Bruker announced the release of the Dimension IconIR nanoscale infrared spectroscopy and chemical imaging system.
2021.07.12
Bruker launches NMR Honey-Profiling 3.0[8]Bruker推出NMR Honey-Profiling 3.0selectscience.net
Bruker launched the latest version of its NMR Honey-Profiling module, expanding its honey reference database and adding geographical and varietal markers to help detect adulteration.
2021.03.10
Reported2021.03.10
GlycoPath closes seed investment round[9]GlycoPath完成种子轮融资prnewswire.com
GlycoPath announced the closing of its seed investment round, with Bruker Corporation participating as a new minority investor. The financial details were not disclosed.
2021.03.10
Reported2021.03.10
GlycoPath and Bruker partner on research assays[9]GlycoPath完成种子轮融资prnewswire.com
GlycoPath and Bruker described a partnership intended to enable wider access to GlycoTyper research assays based on Bruker's MALDI-TOF technology.
2021.01.28
Reported2021.01.28
Avacta and Bruker agree to evaluate COVID-19 assay[10]Avacta与Bruker达成协议评估新冠检测方法finanznachrichten.de
Avacta announced a collaboration agreement with Bruker to assess whether Avacta’s Affimer-based BAMS SARS-CoV-2 assay is suitable as a professional-use in-vitro diagnostic product on Bruker MALDI-TOF instruments for sale in the UK and Europe.
2020.12.18
Reported2020.12.18
Bruker launches FluoroType SARS-CoV-2/Flu/RSV PCR panel in Europe[11]Bruker在欧洲推出FluoroType SARS-CoV-2/Flu/RSV PCR检测面板biospace.com
Bruker announced the launch in Europe of the FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, which detects SARS-CoV-2, influenza A and B, and respiratory syncytial virus. The panel is CE-IVD labelled.
2020.10.19
Reported2020.10.19
Bruker releases PaSER proteomics software[12]布鲁克发布PaSER蛋白质组学软件biospace.com
Bruker announced the release of PaSER, a GPU-based software device for real-time proteomics database searches.
2020.08.09
Bruker announced a collaboration with Utrecht University on mass spectrometry methods[13]布鲁克宣布与乌得勒支大学合作开发质谱方法selectscience.net
Bruker announced a collaboration with Utrecht University to advance the study of protein structures and interactions using mass spectrometry. The work will focus on developing TIMS and PASEF methods, crosslinkers, and XL-MS software for the timsTOF Pro 4D-Proteomics mass spectrometer.

Sources16 sources

Cite this profile: Cite the canonical profile. /brand-wiki/bruker · Editorial policy · How profiles are compiled